976-985 Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 6, 2014, Pages 976-985

  Schmidt, Julie A ^a   Allen, Naomi E ^a   Almquist, Martin ^d   Franceschi, Silvia ^g   Rinaldi, Sabina ^g   Tipper, Sarah J ^a   Tsilidis, Konstantinos K ^a,k   Weiderpass, Elisabete ^e,o,p,q   Overvad, Kim ^r   Tjnøneland, Anne ^s   Boutron Ruault, Marie Christine ^h,i,j   Dossus, Laure ^h,i,j   Mesrine, Sylvie ^h,i,j   Kaaks, Rudolf ^t   Lukanova, Annekatrin ^f,t   Boeing, Heiner ^u   Lagiou, Pagona ^l,m,v   Trichopoulos, Dimitrios ^m,n,v   Trichopoulou, Antonia ^l,n   Palli, Domenico ^w   Krogh, Vittorio ^x   Panico, Salvatore ^y   Tumino, Rosario ^z   Zanetti, Roberto ^aa   Bueno de Mesquita, H Bas ^b,ab,ac   Peeters, Petra H ^b,ac   Lund, Eiliv ^o   Meneńdez, Virginia ^ad   Agudo, Antonio ^ae   Śanchez, María Jośe ^af,ag,ah   Chirlaque, Maria Dolores ^ah,ai   Ardanaz, Eva ^ah,aj   Larranãga, Nerea ^ah,ak   Hennings, Joakim ^f   Sandstrom̈, Maria ^f   Khaw, Kay Tee ^c   Wareham, Nick ^c   Romieu, Isabelle ^g   Gunter, Marc J ^b   Riboli, Elio ^b   Key, Timothy J ^a   Travis, Ruth C ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY OF IOANNINA   (Greece)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m BIOMEDICAL RESEARCH FOUNDATION   (Greece)

ⁿ HELLENIC HEALTH FOUNDATION   (Greece)

^o UNIVERSITY OF TROMSØ   (Norway)

^p CANCER REGISTRY OF NORWAY   (Norway)

^q FOLKHÄLSAN RESEARCH CENTER   (Finland)

^r AARHUS UNIVERSITY   (Denmark)

^s DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^t GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^u GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^v HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^w CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^x NATIONAL CANCER INSTITUTE   (Italy)

^y UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^z Cancer Registry and Histopathology Unit   (Italy)

^aa CPO Centre for Epidemiology and Prevention in Oncology in Piedmont   (Italy)

^ab NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ac UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ad Public Health Dir   (Spain)

^ae CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^af ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^ag Instituto de Investigación Biosanitaria de Granada   (Spain)

^ah CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ai Murcia Regional Health Authority   (Spain)

^aj INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ak BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIATED THYROID CANCER; EUROPE; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MENSTRUAL CYCLE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; AGED; METABOLISM; NUTRITIONAL ASSESSMENT; RISK FACTOR; THYROID NEOPLASMS;

ADULT; AGED; CASE-CONTROL STUDIES; EUROPE; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; PROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS;

EID: 84903384496     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1210-T     Document Type: Article

References (45)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; c2013 [cited 2014 Jan 09]. Available from: http://globocan.iarc.fr
2. McNally RJ, Blakey K, James PW, Gomez Pozo B, Basta NO, Hale J. Increasing incidence of thyroid cancer in Great Britain, 1976-2005: age-period-cohort analysis. Eur J Epidemiol 2012;27:615-22.
3. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009;20:525-31.
4. Morris LG, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg 2010;200:454-61.
5. Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, et al. Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period cohort effects. Ann Oncol 2011;22:957-63.
6. Adami H-O, Hunter DJ, Trichopoulos D. Textbook of cancer epidemiology. 2nd ed. Oxford; New York, NY: Oxford University Press; 2008.
7. Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem 2005;12:2881-91. (Pubitemid 41613364)
8. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 2009;17:1668-75.
9. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-71.
10. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42.
11. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010;126:1702-15.
12. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab 2011;96:E2023-8.
13. Volzke H, Friedrich N, Schipf S, Haring R, Ludemann J, Nauck M, et al. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab 2007;92:4039-45. (Pubitemid 47607658)
14. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, et al. Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol 2010;171:242-52.
15. Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, et al. A pooled analysis of case-control studies of thyroid cancer IV. Benign thyroid diseases. Cancer Causes Control 1999; 10:583-95.
16. Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 2001;93:745-50. (Pubitemid 32695128)
17. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol 2011;12:785-94.
18. Rinaldi S, Lise M, Clavel-Chapelon F, Boutron-Ruault MC, Guillas G, Overvad K, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012;131:E1004-14.
19. Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol 2005;63:161-7. (Pubitemid 41097984)
20. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010;13:242-8.
21. Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J. The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol Lett 2009;30:382-6.
22. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24. (Pubitemid 36313608)
23. Egevad L, Heanue M, Berney D, Fleming K, Ferlay J. Chapter 4: histological groups. In:Curado MP, et al. editors. Cancer incidence in five countries, volume IX. Lyon, France: International Agency for Research on Cancer; 2007. p. 61-6.
24. Rothman KJ, Greenland S, Lash TL. Case-control studies. In:Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 111-27.
25. Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Oestergaard JN, Overvad K, et al. TSH, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 2014; In press.
26. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65. (Pubitemid 40879595)
27. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Endocr Relat Cancer 2005;12:1071-82. (Pubitemid 41815798)
28. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993;22:1189-92. (Pubitemid 24025700)
29. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003;6:407-13. (Pubitemid 36749764)
30. Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Gronbaek H, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1-2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol 2011;38:194-202.
31. Baldys-Waligorska A, Krzentowska A, Golkowski F, Sokolowski G, Hubalewska-Dydejczyk A. The prevalence of benign and malignant neoplasms in acromegalic patients. Pol J Endocrinol 2010;61:29-34.
32. Nose V. Familial thyroid cancer: a review.Mod Pathol 2011;24 Suppl 2: S19-33.
33. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306. (Pubitemid 28065257)
34. Feldt-Rasmussen U. Iodine and cancer. Thyroid 2001;11:483-6. (Pubitemid 32496288)
35. In:Andersson M, de Benoist B, Darnton-Hill I, Delange F, editors. Iodine deficiency in Europe: a continuing public health problem. France: World Health Organization; 2007.
36. Maccario M, Ramunni J, Oleandri SE, Procopio M, Grottoli S, Rossetto R, et al. Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes 1999;23:612-8. (Pubitemid 29276810)
37. Seck T, Scheidt-Nave C, Ziegler R, Pfeilschifter J. Positive association between circulating free thyroxine and insulin-like growth factor l concentrations in euthyroid elderly individuals. Clin Endocrinol 1998;48:361-6. (Pubitemid 28137650)
38. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 2012;44:319-22.
39. Saji M, Akamizu T, Sanchez M, Obici S, Avvedimento E, Gottesman ME, et al. Regulation of thyrotropin receptor gene expression in rat FRTL-5 thyroid cells. Endocrinology 1992;130:520-33.
40. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 763-8. (Pubitemid 46650579)
41. Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N. Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 2002;48:2248-51. (Pubitemid 35397570)
42. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8. (Pubitemid 35340370)
43. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006;118:1279-84. (Pubitemid 43185618)
44. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
45. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972-8. (Pubitemid 43823526)